Exercise Training on Brain Insulin Responsiveness
Launched by UNIVERSITY HOSPITAL TUEBINGEN · Sep 13, 2023
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a single workout can affect how the brain responds to insulin, which is important for managing insulin resistance and obesity. Participants will take part in two different types of exercise sessions: one at a moderate intensity and the other at a high intensity, both of which are performed in a random order. There will also be a period where participants do not exercise, to see how the brain's insulin response changes with and without exercise.
To be eligible for this study, participants should have a body mass index (BMI) between 19.5 and 39 and should not be very active, meaning they do less than 150 minutes of moderate exercise or 75 minutes of vigorous exercise each week. Participants will need to provide written consent to take part and agree to be informed about any important findings during the study. It’s important to note that individuals with certain health conditions, such as diabetes or heart disease, and those who are pregnant or have specific medical implants, cannot participate. Participants can expect to engage in supervised exercise sessions and will help researchers understand the relationship between exercise and brain health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • BMI between ≥ 19.5 to 39 kg/m2-
- • Less than 150 min/week for moderate-intensity physical activity
- • Less than 75 min/week for Vigorous- intensity exercise (WHO recommendations for regular physical activity of adults)
- • Written consent to participate in the study
- • Written consent to be informed about incidental findings
- • Exclusion Criteria
- • Type 2 diabetes, cardiovascular diseases such as chronic heart failure, myocardial infarction, status post stroke
- • Limitations to participate in ergometer-based exercise (balance and coordination disorders, orthopedic problems, ...)
- • Insufficient knowledge of the German language
- • Persons who cannot legally give consent
- • Pregnancy or lactation
- • History of severe mental or somatic disorders including neurological diseases (incl. epileptic seizures and migraines)
- • Taking psychotropic drugs
- • Taking medications that influence glucose metabolism
- • Regular use of analgesic drugs
- • Taking anticoagulant agents
- • Previous bariatric surgery
- • Acute infection within the last 4 weeks
- • Hemoglobin values less than 12g/dl for women, less than 14 g/dl for men
- • Other diseases that in the opinion of the investigator may jeopardize the success of the study or indicate a risk to the volunteer
- • Current participation in a lifestyle intervention study or a pharmaceutical study
- • Metal implants which cannot be removed as pacemakers, artificial heart valve, electrical devices as insulin pumps, large tattoos, retainer over more than 4 teeth, contraceptive coil, implanted magnetic metal parts as screws or plates after a surgery
- • Persons with claustrophobia
- • Temperature-sensitive person
- • Persons with tinnitus or increased sensitivity to loud sounds
About University Hospital Tuebingen
University Hospital Tübingen is a leading academic medical institution in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its multidisciplinary expertise and cutting-edge facilities to develop new therapeutic strategies and improve patient outcomes. With a strong focus on translational medicine, University Hospital Tübingen collaborates with various stakeholders, including pharmaceutical companies and research organizations, to facilitate the efficient and ethical conduct of trials across a wide range of medical disciplines. Their dedication to patient-centered research and rigorous scientific standards positions them at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tübingen, , Germany
Patients applied
Trial Officials
Andreas L. Birkenfeld, MD
Study Director
Institute for Diabetes research and Metabolic Diseases at the University of Tubingen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported